Maturity-onset diabetes of the young type 2
MONDO:0007453Monogenic diabetes caused by inactivating mutation(s) in the GCK gene, encoding glucokinase. Heterozygous GCK mutations may manifest as mild hyperglycemia, which is not progressive, and usually requires no treatment. Homozygous GCK mutations result in permanent neonatal diabetes.
Also known as: GCK maturity-onset diabetes of the young (disease), GCK-associated diabetes mellitus, MODY 2 monogenic diabetes type 2, MODY, type II, MODY2, glucokinase-associated diabetes mellitus, maturity onset diabetes of the Young, type 2, maturity-onset diabetes of the young (disease) caused by mutation in GCK
39 clinical trials for this condition and its sub-types, 4 tagged with Maturity-onset diabetes of the young type 2 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New pill could tame rare genetic diabetes
Disease control Recruiting nowThis study tests a new drug called dorzagliatin in 44 adults with a rare, inherited form of diabetes (GCK-MODY). The drug works by activating a key enzyme to help the body better control blood sugar. Participants will receive both the drug and a placebo at different times to see …
Phase 2 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Can a Vitamin-Like pill boost fat burning on a keto diet?
Knowledge-focused Recruiting nowThis study looks at how a supplement called nicotinamide riboside (NR) and a low-carb, high-fat 'ketogenic' diet affect the way the body burns fat and uses energy. Researchers will measure changes in metabolism in 100 overweight or obese adults. Participants will eat a standard d…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study tests if cutting insulin boosts heart health in type 1 diabetes
Knowledge-focused Recruiting nowThis early-phase study looks at whether reducing high insulin levels (common in type 1 diabetes) with an SGLT2 inhibitor can improve heart and blood sugar health. Researchers will compare people with type 1 diabetes, those with a mild genetic diabetes (GCK-MODY), and healthy volu…
Early phase 1 • Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC